Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05222607 · ClinicalTrials.gov registry record
Longitudinal Evaluation and Real-world Evidence of NT201
A clinical trial, sponsored by Merz North America.
- Terminated
- Registry status
- 11
- Enrollment target
NCT05222607: Clinical Trial study, sponsored by Merz North America.
NCT05222607 is a clinical trial that was terminated before completion, run by Merz North America. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05222607 was terminated before completion, sponsored by Merz North America.
- TERMINATED
- Registry status
- 11 participants
- Enrollment target
Study Summary
This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A (BoNT-A) treatment naïve participants.
Primary Outcome
Explore the effectiveness of the incobotulinumtoxinA injections in treatment naïve participants for facial cosmetic procedures during up to 3 years continuous treatment exposure, as measured by assessment of FACE-Q Patient-Perceived Age Visual Analogue Scale mean change from first treatment visit to the 4-to-6 weeks timepoint.
Interventions
- DRUG IncobotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2023-02-10 |
| Est. Completion | 2023-05-18 |
Why NCT05222607 stopped before completion
NCT05222607 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which IncobotulinumtoxinA is the first listed.
NCT05222607 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05222607 about?
NCT05222607 is a clinical study titled "Longitudinal Evaluation and Real-world Evidence of NT201". This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A (BoNT-A) treatment naïve participants.
What is the current status of trial NCT05222607?
This trial is currently terminated. The enrollment target is 11 participants. The study started on 2023-02-10. Estimated completion is 2023-05-18.
What interventions are being tested in trial NCT05222607?
The interventions under investigation include: IncobotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT05222607?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI